title: Roux-en-Y gastric bypass in the treatment of non-classic congenital adrenal hyperplasia due to 11-hydroxylase deficiency.
abstract: Non-classic adrenal hyperplasia (NCAH) has been associated with insulin resistance (IR). Therapies such as metformin, thiazolidinediones and lifestyle alterations improve IR and also ameliorate the biochemical and clinical abnormalities of NCAH, much as they do in polycystic ovarian syndrome (PCOS). More recently, bariatric surgery, such as Roux-en-Y gastric bypass (RYGBP), has also been associated with improvement in IR and amelioration of PCOS and may, therefore, be beneficial in NCAH. We report a case of a 39-year-old, deaf-mute, obese woman with NCAH due to 11-hydroxylase deficiency who underwent RYGBP followed by improvement of NCAH manifestations. She was initially treated with metformin and pioglitazone, which lowered serum 11-deoxycortisol from 198 ng/dl (<51) to 26 ng/dl. Five weeks after undergoing RYGBP her body mass index fell from 44.18 kg/m(2) to 39.54 kg/m(2) and, despite not taking metformin or pioglitazone, serum 11-deoxycortisol remained normal at <40 ng/dl. Concurrently and subsequently, her NCAH symptoms, for example, alopecia, hirsutism and irregular menses normalised as well. We conclude that RYGBP, like other interventions that reduce IR, may be another way of treating non-classic 11-hydroxylase deficiency in selected patients.
authors.affiliation: Department of Medicine, Woodhull Medical Center, Brooklyn, New York, USA.
authors.forename: Amir
authors.initials: A
authors.lastname: Kalani
authors.forename: Nithin
authors.initials: N
authors.lastname: Thomas
authors.forename: Alan
authors.initials: A
authors.lastname: Sacerdote
authors.forename: Gül
authors.initials: G
authors.lastname: Bahtiyar
mesh_terms: D000312:Adrenal Hyperplasia, Congenital / Q000601:surgery*; D000328:Adult; D005260:Female; D015390:Gastric Bypass; D006801:Humans